help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Barontini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Barontini, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*17ALPHA-HYDROXYPROGESTERONE
*ESTRADIOL
*ESTRONE
*MENOTROPINS
*TESTOSTERONE
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 8 3772-3778
Copyright © 2001 by The Endocrine Society

Other Original Articles

Disruption of the Synchronous Secretion of Leptin, LH, and Ovarian Androgens in Nonobese Adolescents with the Polycystic Ovarian Syndrome

J. D. Veldhuis, S. M. Pincus, M. C. Garcia-Rudaz, M. G. Ropelato, M. E. Escobar and M. Barontini

Division of Endocrinology (J.D.V.), Department of Internal Medicine, General Clinical Research Center and Center for Biomathematical Technology, University of Virginia School of Medicine, Charlottesville, Virginia 22908; (S.M.P.), Guilford, Connecticut 06437; and Centro de Investigaciones Endocrinologicas (CEDIE) (M.C. G.-R., M.G.R., M.E.E., M.B.), Hospital de Niños "R. Gutierrez," 1425 Buenos Aires, Argentina

Address all correspondence and requests for reprints to: J. D. Veldhuis, Division of Endocrinology, Department of Internal Medicine, University of Virginia School of Medicine, P.O. Box 800202, Charlottesville, Virginia 22908-0202. E-mail: JDV{at}virginia.edu

Abstract

The present study probes putative disruption of hypothalamic control of multihormone outflow in polycystic ovarian syndrome by quantitating the joint synchrony of leptin and LH release in adolescents with this syndrome and eumenorrheic controls. To this end, hyperandrogenemic oligo- or anovulatory patients with polycystic ovarian syndrome (n = 11) and healthy girls (n = 9) underwent overnight blood sampling every 20 min for 12 h to monitor simultaneous secretion of leptin (immuno-radiometric assay), LH (immunofluorometry), and androstenedione and T (RIA). Synchronicity of paired leptin-LH, leptin-androstenedione, and leptin-T profiles was appraised by two independent bivariate statistics; viz., lag-specific cross-correlation analysis and pattern-sensitive cross-approximate entropy. The study groups were comparable in chronological and postmenarchal age, body mass index, fasting plasma insulin/glucose ratios, and serum E2 concentrations. Overnight mean (± SEM) serum leptin concentrations were not distinguishable in the two study groups at 30 ± 4.8 (polycystic ovarian syndrome) and 32 ± 7.4 µg/liter (control). Serum LH concentrations were elevated at 9.5 ± 1.4 in girls with polycystic ovarian syndrome vs. 2.8 ± 0.36 IU/liter in healthy subjects (P = 0.0015), androstenedione at 2.8 ± 0.30 (polycystic ovarian syndrome) vs. 1.2 ± 0.11 ng/ml (control) (P = 0.0002), and T at 1.56 ± 0.29 (polycystic ovarian syndrome) vs. 0.42 ± 0.06 ng/ml (P < 0.0001). Cross-correlation analysis shows that healthy adolescents maintained a positive relationship between leptin and LH release, wherein the latter lagged by 20 min (P < 0.01). No such association emerged in girls with polycystic ovarian syndrome. In eumenorrheic volunteers, leptin and androstenedione concentrations also covaried in a lag-specific manner (0.0001 < P < 0.01), but this linkage was disrupted in patients with polycystic ovarian syndrome. Anovulatory adolescents further failed to sustain normal time-lagged coupling between leptin and T (P < 0.01). Approximate entropy calculations revealed erosion of orderly patterns of leptin release in polycystic ovarian syndrome (P = 0.012 vs. control). Cross-entropy analysis of two-hormone pattern regularity disclosed marked disruption of leptin and LH (P = 0.0099), androstenedione and leptin (P = 0.0075) and T-leptin (P = 0.019) synchrony in girls with polycystic ovarian syndrome.

In summary, hyperandrogenemic nonobese adolescents with oligo- or anovulatory polycystic ovarian syndrome manifest: 1) abrogation of the regularity of monohormonal leptin secretory patterns, despite normal mean serum leptin concentrations; 2) loss of the bihormonal synchrony between leptin and LH release; and 3) attenuation of coordinate leptin and androstenedione as well as leptin and T output. In ensemble, polycystic ovarian syndrome pathophysiology in lean adolescents is marked by vivid impairment of the synchronous outflow of leptin, LH and androgens. Whether analogous disruption of leptin-gonadal axis integration is ameliorated by therapy and/or persists into adulthood is not known.

LEPTIN IS A signaling peptide produced in fat cells, which supervises neuroendocrine adaptations to altered nutritional status (1, 2, 3, 4, 5, 6, 7). Leptin receptors are expressed in various hypothalamic nuclei and in the rodent mediate feedback from adipose tissue on appetite, thermoregulatory, reproductive, somatotropic, thyrotropic, and corticotropic regulatory centers (8, 9, 10). Leptin secretion is modulated by total fat cell mass, sex steroids, GH, glucocorticoids, insulin, and sympathetic activity (11, 12, 13, 14, 15). Mutations of the genes encoding leptin or its receptor are accompanied by obesity and disruption of neuroendocrine function (8, 9), such as hypogonadotropic hypogonadism (2, 8, 9, 16, 17).

Elevated leptin secretion in obesity is associated with altered LH production (3, 4, 5, 6, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29). Accordingly, coexistent adiposity may confound the facile interpretation of any pathophysiological linkage between leptin and LH secretion in reproductive diseases accompanied by obesity, such as a significant subset of patients with polycystic ovarian syndrome (PCOS) (18, 19, 21, 30, 31, 32, 33, 34, 35, 36, 37, 38). Indeed, little is known about leptin-LH coupling in nonobese individuals with PCOS (39). This issue may be especially significant in PCOS, wherein clinical evidence points to alterations in both leptin and gonadotropin secretion (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52). Accordingly, the present study appraises the simultaneous output of leptin and LH in nonobese adolescents with PCOS and eumenorrheic controls matched for body mass index.

Materials and Methods

Clinical protocol

Volunteers provided institutionally approved individual assent and parental consent before participation. PCOS was defined by clinical androgen excess (acne and Ferriman-Gallway hirsutism score >= 9), biochemical hyperandrogenism (an elevated morning serum concentration of T or androstenedione), and peripubertal onset of oligo- or amenorrhea without disease of the thyroid, PRL, or adrenal axes (53). Adolescents with PCOS (n = 11) and eumenorrheic late-pubertal girls (n = 9) were of comparable chronological as well as postmenarchal ages: Table 1Go. Anovulatory patients with PCOS (n = 4) were sampled at a random time, whereas oligoovulatory patients and normal controls were studied within 3–5 days of bleeding. To monitor multiple hormone release, blood was withdrawn at 20-min intervals for 12 h overnight (1900–0700 h clocktime). Although 20-min sampling was required to limit total blood loss, a higher frequency of blood sampling may detect more subordinate variations in hormone outflow.


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical characteristics of oligo- and anovulatory adolescents with PCOS and eumenorrheic controls

 
Assays

Concentrations of LH, leptin, T, and androstenedione were measured in each serum sample using either immunofluorometry (LH) or RIA (both androgens) (40, 41, 42). Leptin was quantitated by immuno-radiometric assay with an assay sensitivity of 0.1 µg/liter and median intra and interassay coefficients of variation of 1.2% and 3.5% (23). Insulin, SHBG, estrone, E2, dehydroepiandrosterone-sulfate, 17{alpha}-hydroxyprogesterone, and FSH were assayed fasting in overnight serum pools, as described previously (40, 41, 42).

Assessment of monohormonal pattern regularity and bihormonal secretory synchrony

a) Approximate entropy (ApEn) calculation. ApEn comprises a family of translation-, model-, and scale-independent regularity statistics designed to compare the relative orderliness of time series (54, 55). Univariate ApEn quantifies pattern reproducibility in serial measurements and thus complements conventional pulse detection and cosinor analyses (54, 55, 56, 57). Higher ApEn values denote greater disorderliness of secretory patterns, as observed for pituitary tumoral production of GH, ACTH, and PRL and (58, 59, 60); the secretion of GH, LH, T, ACTH, cortisol, and insulin in aging (57, 59, 61); and GH release in women and pubertal girls compared with men and boys (62, 63).

To compute ApEn for N serial observations, two input parameters, m and r, are fixed where m represents the pattern-comparison window size and r the de facto statistical tolerance for testing pattern recurrence. Normalized ApEn defines r as a percentage of the intersample SD of each time series, e.g. 20–35%, thereby maintaining scale invariance (62, 64). In the present analysis, m was assigned a value of 1, which serves to evaluate the statistical consistency of contiguous (sample-by-sample) data patterns. The parameter r was set to 35% as appropriate for shorter time series (65). The foregoing ApEn parameters, designated by ApEn (1,35%), provide a replicable ApEn statistic with an approximate SD of 0.06–0.08 (62, 64, 66). A normalized ratio of observed-to-random ApEn was calculated for each time series as the mean ratio of observed to random ApEn values calculated by shuffling the original data series times 1000 times (65).

b) Cross-correlation analysis.Cross-correlation analysis quantitates the strength of the simple linear relationship (if any) between successively paired measurements in two equally spaced time series considered at various relative lag times (67, 68). This statistic evaluates Pearson’s correlation coefficients, or r values, for the matched series viewed simultaneously (zero time lag) and at various integral time lags. Error estimates for each cross-correlation r value were propagated from the pooled sample variances corrected for total series length and the number of lag units considered (68). The overall statistical significance of group r values at any given lag interval was tested via the one-sample Kolmogorov-Smirnov statistic of the null hypothesis that the corresponding z score distribution of observed r values is random normal with zero mean and unit SD (67).

c) Cross-ApEn computation. Cross-ApEn is the bivariate analog of the ApEn statistic (above). This metric quantifies the joint synchrony of patterns in paired hormone series using standardized (z-score transformed) data (57, 59, 69). The cross-ApEn ratio (observed-to-randomly shuffled series, above) was used to normalize cross-ApEn for each hormone pair.

d) Complementarity of cross-ApEn and cross-correlation analyses. The foregoing statistical techniques are complementary, since cross-correlation analysis monitors the strength of linear lag-specific correlations and cross-ApEn quantifies the degree of lag-independent pattern synchrony between paired time series (56, 57).

Statistical analysis

An unpaired two-tailed t test with unequal variance was applied to compare log-transformed ApEn and cross-ApEn values in the two study groups. P < 0.05 was construed as statistically significant. Data are presented as the mean ± SEM. Multiple linear regression analyses were not performed in view of the small group sizes.

Results

Figure 1Go illustrates serum leptin and LH concentration profiles in 3 of 9 normal girls and 3 of 11 PCOS patients, each of whom underwent repetitive blood sampling at 20-min intervals for 12 h overnight. Mean (and integrated) serum leptin concentrations were comparable in the two study groups at respectively 32 ± 7.4 µg/liter (and 23,090 ± 5,300 µg/liter·min) [control], and 30 ± 4.8 ng/liter (and 21,700 ± 3,500 µg/liter·min) [PCOS]. In adolescents with PCOS, mean serum concentrations of LH, androstenedione, T, and estrone were elevated, SHBG suppressed, and insulin, insulin/glucose ratios, E2, and GH normal: Table 1Go. Chronological and postmenarchal ages, body mass indices and fasting serum insulin concentrations were comparable in the two groups (Table 1Go).



View larger version (30K):
[in this window]
[in a new window]
  		Figure 1. Illustrative 12-h profiles of serum leptin and LH concentrations measured by RIA and immunofluorometry, respectively, in blood sampled at 20-min intervals overnight in the fasting state in three eumenorrheic healthy adolescents (control) and three hyperandrogenemic oligo- or anovulatory patients with PCOS. The study groups were comparable in chronological and postmenarchal ages, body mass indices, and fasting serum insulin concentrations. Vertical bars associated with the data points denote within-assay sample SDs (Materials and Methods).

 
Healthy adolescents exhibited a strongly positive cross-correlation between overnight sample-by-sample leptin and LH release at a 20-min LH lag time (i.e. leptin release preceded that of LH by 20 min) (P < 0.01), as illustrated in Fig. 2Go. This relationship was absent in girls with PCOS. Normal girls also maintained positive leptin-androstenedione cross-correlations over a range of androstenedione lags of 100–140 min (0.0001 < P < 0.01): Fig. 3AGo. In contrast, patients with PCOS developed a negative cross-correlation between leptin and androstenedione and only at a leptin lag interval of 140 min (P < 0.001). Leptin-T cross-correlations were negative in both cohorts: Fig. 3BGo. However, whereas normal adolescents sustained a broad window of leptin lag of -20 to + 100 min (wherein changes in leptin followed those of T, < 0.0001 < P < 0.01), whereas PCOS patients showed a restricted leptin lag intervals of +40 and +60 min (0.001 < P < 0.01).



View larger version (23K):
[in this window]
[in a new window]
  		Figure 2. Median and absolute range of cross-correlation coefficients (r, values) plotted against various lag times (intervals in min separating the successively paired serum hormone concentrations) in a group of 9 normal girls (control, upper panels) and 11 patients with PCOS (lower panels). Cross-correlation analysis was applied to overnight simultaneous profiles of serum leptin and LH concentrations. P values at various time lags reflect the statistical significance of the group correlation coefficients under a null hypothesis of purely chance associations between the two hormones (Materials and Methods). A positive time lag (right side of each subpanel) denotes that a change in the concentration of the first-named hormone precedes that of the second by the indicated time lag (and, conversely, for a negative time lag).

 


View larger version (27K):
[in this window]
[in a new window]
  		Figure 3. Median and range of cross-correlation coefficients for serum androstenedione-leptin (A) and T-leptin (B) concentration profiles in 9 control (upper) and 11 PCOS patients (lower). Data are presented as defined in the legend of Fig. 2Go.

 
The univariate ApEn statistic was used to quantitate pattern regularity of leptin secretion: Fig. 4Go. In eumenorrheic girls, the mean ApEn ratio for leptin profiles was 0.865 ± 0.046 (P < 0.005 vs. random); in PCOS patients, this value rose to 1.016 ± 0.017 (P = NS vs. randomly shuffled leptin series, and P = 0.012 vs. healthy controls). These findings establish highly irregular patterns of monohormonal leptin release in PCOS.



View larger version (12K):
[in this window]
[in a new window]
  		Figure 4. Approximate entropy [ApEn (1,35%)] ratios quantifying the regularity of overnight serum leptin concentration profiles in individual healthy adolescent girls (controls, left, n = 9) and patients with PCOS (right, n = 11). ApEn ratios below unity denote more orderly patterns of hormone release, and conversely. Numerical values are the group mean ± SEM.

 
ApEn ratios for LH (P = 0.015), androstenedione (P = 0.004) and T (P = 0.0019) were also elevated in PCOS patients, denoting marked loss of orderliness: Fig. 5Go.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 5. ApEn (1,35%) ratios of LH, androstenedione, and T time series in individual normal and PCOS adolescents. Data are presented as defined in Fig. 4Go.

 
The bivariate cross-ApEn ratio was applied to quantify joint (two-hormone) pattern synchrony. Cross-ApEn ratios for leptin and LH (P = 0.0099), leptin and androstenedione (P = 0.0075), and leptin and T (P = 0.019) were elevated in patients with PCOS: Fig. 6Go. These contrasts identify significant marked erosion of bivariate synchrony.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 6. Cross-approximate entropy [cross-ApEn (1,35%)] ratios quantitating the joint synchrony of paired 12-h leptin and LH (A), leptin and androstenedione (B), and leptin and T (C) release in normal pubertal girls (controls, n = 9) compared with patients with PCOS (n = 11). See legend of Fig. 4Go for data presentation.

 
Anovulatory and oligoovulatory patients did not differ in any of the foregoing measures.

Discussion

The present investigation compares patterns of monohormonal leptin and bihormonal (coordinate) leptin-LH, leptin-androstenedione, and leptin-T release in nonobese hyperandrogenemic oligo- and anovulatory adolescents with PCOS and eumenorrheic girls of comparable age, body mass index, and fasting serum insulin concentrations. From a univariate perspective, the patterns of overnight leptin release were markedly irregular in PCOS. From a bivariate perspective, the coordinate release of leptin and LH, leptin and androstenedione, and leptin and T was disrupted in this disorder, denoting disruption of leptin-gonadal axis coupling.

Healthy adolescent girls maintained orderly patterns of leptin secretion, as quantitated objectively by the ApEn statistic (56, 58, 65). The latter metric provides a sensitive and objective index of alterations in within- and between-axis feedback control (57, 62, 65). ApEn quantitation differs from pulse detection and cosinor analysis by discriminating degrees of subpattern reproducibility on a sample-by-sample basis independently of pulse enumeration or rhythm assessments (55, 57, 58, 59, 61, 64). In the present study, application of the ApEn statistic unveiled profound disruption of leptin pattern regularity in adolescent with PCOS. In fact, mean observed ApEn ratios for leptin in PCOS were statistically indistinguishable from randomly shuffled data series.

The mechanisms that govern orderly leptin release are not known, but presumably include both systemic (neuroendocrine) and local (adipocyte) factors (see Introduction). Although detailed body compositional data were not analyzed here, the two study groups had comparable body mass indices and fasting serum insulin concentrations. Moreover, integrated (12-h) serum leptin concentrations were equivalent. Thus, the leptin secretory derangement in adolescents with PCOS is not so readily attributable to any of these factors (19, 24). Other potential mechanisms include the abnormal sex-steroid milieu in PCOS, inasmuch as androgen can suppress and estrogen stimulate leptin secretion (8, 11, 15, 27, 70). However, E2 levels were similar in the two groups studied here.

Two-hormone synchrony was assessed by statistically independent methodologies. Cross-correlation analysis showed abrogation of the normal positive time-lagged relationship between paired leptin and LH release, and cross-ApEn analysis identified significant distortion of the joint pattern synchrony of leptin and LH secretion in adolescents with PCOS. Given the different biomathematical principles underlying the foregoing measures of bihormonal coupling (57, 67), their thematically consonant predictions provide unique evidence for loss of normal leptin-LH linkages in PCOS.

Eumenorrheic controls maintained a significantly positive and consistently time-lagged linear correlation between leptin and androstenedione release and a negative time-lagged relationship between leptin and T output. Both cross-correlations were reduced in patients with PCOS. Likewise, the pattern-dependent synchrony observed in healthy girls between leptin and androstenedione as well as between leptin and T release, as quantitated by the cross-ApEn statistic, was significantly attenuated in PCOS. Thus, both analytical assessments demonstrate unequivocal erosion of coordinate leptin-androstenedione and leptin-T secretion. The precise basis for this interaxis pathophysiology in adolescents with PCOS is not yet known. However, the foregoing findings would be consistent with aberrant feedback by ovarian androgen (or its aromatized product, estrogen) on leptin secretion or anomalous feedforward by leptin on the hypothalamo-pituitary-gonadal axis (8, 9, 14, 17, 71, 72, 73). Indeed, since leptin can inhibit in vitro androgen biosynthesis by gonadal cells, and, conversely, androgens appear to suppress leptin production in vivo 119061} (13, 14, 15, 27, 74), impairment of bidirectional (leptin-androgen and androgen-leptin) communication is plausible in PCOS. Although dehydroepiandrosterone-sulfate levels were normal here, altered adrenal androgen production might contribute further to the observed leptin-androgen asynchrony (8, 70).

In summary, the present investigations delineate disruption of the orderly release of leptin and erosion of the synchrony between leptin and each of LH, androstenedione, and T secretion in nonobese adolescents with PCOS. Thereby, we establish joint dysregulation of the leptin and gonadotropin-gonadal axes despite mean euleptinemia. Whether this interaxis pathophysiology is reversible to therapeutic intervention and occurs analogously in the adult with PCOS will require further study.

Acknowledgments

We acknowledge the contribution of the nursing staff of the Division of Endocrinology of "R Gutierrez" Hospital and Mrs. Maria Gabriela Gutierrez Moyano for her excellent technical assistance.

We thank Patsy Craig for her skillful preparation of the manuscript and Paula P. Azimi for the deconvolution analysis, data management, and graphics. This focused report necessarily omits many primary references because of editorial constraints. The authors therefore acknowledge numerous colleagues who have made earlier foundational observations.

Footnotes

This work was supported in part by Grant PID-4202 from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). M.B. is a Senior Investigator of CONICET, Argentina, and M.C.G.-R. is a Research Fellow. This work was supported in part by NIH Grant MO-1-RR-00847 to the General Clinical Research Center of the University of Virginia Health Sciences Center, NICHD/NIH through cooperative agreement U-54 HD-28934 as part of the Specialized Cooperative Centers Program in Reproduction Research, and NIDDK/SBIR R44 DK-54104 (to S.P.). This work was supported in part by grants Carrillo-Oñativia 2000 from Ministerio de Salud de la Nacion and from Fundacion Alberto J. Roemmers.

Abbreviations: ApEn, Approximate entropy; PCOS, polycystic ovarian syndrome.

Received January 10, 2001.

Accepted April 5, 2001.

References

  1. Ahima RS, Prabakaran D, Mantzoros C, et al. 1996 Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252[CrossRef][Medline]
  2. Barash IA, Cheung CC, Weigle DS, et al. 1996 Leptin is a metabolic signal to the reproductive system. Endocrinology 137:3144–3147[Abstract]
  3. Bergendahl M, Evans WS, Pastor CL, Patel A, Iranmanesh A, Veldhuis JD 1999 Short-term fasting suppresses leptin and (conversely) activates disorderly GH secretion in mid-luteal phase women. J Clin Endocrinol Metab 84:883–894[Abstract/Free Full Text]
  4. Bergendahl M, Iranmanesh A, Evans WS, Veldhuis JD 2000 Short-term fasting selectively suppresses leptin pulse mass and 24-hour rhythmic leptin release in healthy mid-luteal phase women without disturbing leptin pulse frequency or its entropy control (pattern orderliness). J Clin Endocrinol Metab 85:207–213[Abstract/Free Full Text]
  5. Boden G, Chen X, Mozzoli M, Ryan I 1996 Effects of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 81:3419–3423[Abstract]
  6. Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF 1996 Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metab 81:4162–4165[Abstract/Free Full Text]
  7. Karlsson C, Stenlof K, Johannsson G, et al. 1998 Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men. Eur J Endocrinol 138:408–414[Abstract]
  8. Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM 1997 Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 94:1023–1028[Abstract/Free Full Text]
  9. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG 1996 Identification of targets on leptin action in rat hypothalamus. J Clin Invest 98:1101–1106[Medline]
  10. Quintela M, Senaris R, Heiman ML, Casanueva FF, Dieguez C 1997 Leptin inhibits in vitro hypothalamic somatostatin and somatostatin mRNA levels. Endocrinology 138:5641–5644[Abstract/Free Full Text]
  11. Elbers JM, Asscheman H, Seidell JC, Frolich M, Meinders AE, Gooren LJ 1997 Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab 82:3267–3270[Abstract/Free Full Text]
  12. Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS 1997 Leptin inhibition of the hypothalamic-pituitary-adrenal axis response to stress. Endocrinology 138:3859–3863[Abstract/Free Full Text]
  13. Palmert MR, Radovick S, Boepple PA 1998 The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty. J Clin Endocrinol Metab 83:1091–1096[Abstract/Free Full Text]
  14. Shimizu H, Shimomura Y, Nakanishi Y, et al. 1997 Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 154:285–292[Abstract/Free Full Text]
  15. Wabitsch M, Blum WF, Muche R, et al. 1997 Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest 100:808–813[Medline]
  16. Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier JS 1997 Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 99:391–395[Medline]
  17. Nagatani S, Guthikonda P, Thompson RC, Tsukamura H, Maeda KI, Foster DL 1998 Evidence for GnRH regulation by leptin: leptin administration prevents reduced pulsatile LH secretion during fasting. Neuroendocrinology 67:370–376[CrossRef][Medline]
  18. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS 1990 Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 32:213–220[Medline]
  19. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SSC 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 81:2854–2864[Abstract/Free Full Text]
  20. Plymate SR, Fariss BL, Bassett ML, Matej L 1981 Obesity and its role in polycystic ovary syndrome. J Clin Endocrinol Metab 52:1246–1248[Abstract/Free Full Text]
  21. Taylor AE, McCourt B, Martin KA, et al. 1997 Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2248–2256[Abstract/Free Full Text]
  22. Arrovo A, Laughlin GA, Morales AJ, Yen SSC 1997 Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 82:3728–3733[Abstract/Free Full Text]
  23. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M 1996 Radioimmunoassay of leptin in human plasma. Clin Chem 42:942–946[Abstract/Free Full Text]
  24. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A 1988 The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 66:131–139[Abstract/Free Full Text]
  25. Huber-Buchholz M-M, Carey DGP, Norman RJ 1999 Restoration of reproductive potential by lifestyle modificaton in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84:1470–1474[Abstract/Free Full Text]
  26. Lonnqvist F, Nordfors L, Jansson M, Thorne A, Schallling M, Arner P 1997 Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 99:2398–2404[Medline]
  27. Licinio J, Negra AB, Mantzoros C, et al. 1998 Sex differences in circulating human leptin pulse amplitude: clinical implications. J Clin Endocrinol Metab 83:4140–4147[Abstract/Free Full Text]
  28. Dale PO, Tanbo T, Vaaler S, Åbyholm T 1992 Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: Evidence of two distinct populations. Fertil Steril 58:487–491[Medline]
  29. Wadden TA, Considine RV, Foster GD, Anderson DA, Sarwer DB, Caro JS 1998 Short- and long-term changes in serum leptin in dieting obese women: effects of caloric restriction and weight loss. J Clin Endocrinol Metab 83: 214–218
  30. Jacobs HS, Conway GS 1999 Leptin, polycystic ovaries and polycystic ovary syndrome. [Review] [70 refs]. Hum Reprod Update 5:166–171[Abstract/Free Full Text]
  31. El O, Ghalia AA, Khalifa A, Mahfouz H, El S, Shoieb N 1999 Serum leptin as an additional possible pathogenic factor in polycystic ovary syndrome. Clin Biochem 32:71–75[CrossRef][Medline]
  32. Vicennati V, Gambineri A, Calzoni F, et al. 1998 Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47:988–992[CrossRef][Medline]
  33. Gennarelli G, Holte J, Wide L, Berne C, Lithell H 1998 Is there a role for leptin in the endocrine and metabolic aberrations of polycystic ovary syndrome? Hum Reprod 13:535–541[Abstract/Free Full Text]
  34. Micic D, Macut D, Popovic V, et al. 1997 Leptin levels and insulin sensitivity in obese and non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol 11:315–320[Medline]
  35. Mantzoros CS, Dunaif A, Flier JS 1997 Leptin concentrations in the polycystic ovary syndrome [see comments]. J Clin Endocrinol Metab 82:1687–1691[Abstract/Free Full Text]
  36. Laughlin GA, Morales AJ, Yen SS 1997 Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia [see comments]. J Clin Endocrinol Metab 82:1692–1696[Abstract/Free Full Text]
  37. Rouru J, Anttila L, Koskinen P, et al. 1997 Serum leptin concentrations in women with polycystic ovary syndrome [see comments]. J Clin Endocrinol Metab 82:1697–1700[Abstract/Free Full Text]
  38. Chapman IM, Wittert GA, Norman RJ 1997 Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. Clin Endocrinol 46:175–181[CrossRef][Medline]
  39. Sir-Petermann T, Piwonka V, Perez F, Maliqueo M, Recabarren SE, Wildt L 1999 Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome? Hum Reprod 14:1435–1439[Abstract/Free Full Text]
  40. Garcia-Rudaz MC, Ropelato MG, Escobar ME, Veldhuis JD, Barontini M 1998 Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome. Eur J Endocrinol 139:621–630[Abstract]
  41. Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M 2001 Disruption of the joint synchrony of luteinizing hormone, testosterone and androstenedione secretin in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:72–79[Abstract/Free Full Text]
  42. Ropelato MG, Garcia-Rudaz C, Castro-Fernandez C, et al. 1999 A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 84:4629–4636[Abstract/Free Full Text]
  43. Apter D, Butzow T, Laughlin GA, Yen SS 1994 Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 79:119–125[Abstract]
  44. Christman GM, Randolph JF, Kelch RP, Marshall JC 1991 Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease. J Clin Endocrinol Metab 47:155–189
  45. De Leo V, Lanzetta D, D’Antona D, La Marca A, Morgante G 1998 Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:99–102[Abstract/Free Full Text]
  46. Daniels TL, Berga SL 1997 Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab 82:4179–4183[Abstract/Free Full Text]
  47. de Ziegler D, Steingold K, Cedars M, et al. 1989 Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. J Clin Endocrinol Metab 68:1111–1117[Abstract/Free Full Text]
  48. Dunaif A, Longcope C, Canick J, Badger TM, Crowley Jr WF 1985 The effects of the aromatase inhibitor {Delta}1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease. J Clin Endocrinol Metab 60:773–780[Abstract/Free Full Text]
  49. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC 1998 Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by E2 and progesterone. J Clin Endocrinol Metab 83:582–590[Abstract/Free Full Text]
  50. Porcu E, Venturoli S, Magrini O, et al. 1987 Circadian variations of luteinizing hormone can have two different profiles in adolescent anovulation. J Clin Endocrinol Metab 65:488–493[Abstract/Free Full Text]
  51. Mantzoros CS, Cramer DW, Liberman RF, Barbieri RL 2000 Predictive value of serum and follicular fluid leptin concentrations during assisted reproductive cycles in normal women and in women with the polycystic ovarian syndrome. Hum Reprod 15:539–544[Abstract/Free Full Text]
  52. Lindheim SR, Sauer MV, Carmina E, Chang PL, Zimmerman R, Lobo RA 2000 Circulating leptin levels during ovulation induction: relation to adiposity and ovarian morphology. Fertil Steril 73:493–498[CrossRef][Medline]
  53. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Current issues in endocrinology and metabolism: polycystic ovary syndrome. Boston: Blackwell 377–384
  54. Pincus SM 1991 Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA 88:2297–2301[Abstract/Free Full Text]
  55. Pincus SM, Keefe DL 1992 Quantification of hormone pulsatility via an approximate entropy algorithm. Am J Physiol 262:E741–E754
  56. Veldhuis JD, Pincus SM 1998 Orderliness of hormone release patterns: a complementary measure to conventional pulsatile and circadian analyses. Eur J Endocrinol 138:358–362[CrossRef][Medline]
  57. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD 1996 Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci USA 93:14100–14105[Abstract/Free Full Text]
  58. Hartman ML, Pincus SM, Johnson ML, et al. 1994 Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest 94:1277–1288
  59. van den Berg G, Pincus SM, Veldhuis JD, Frolich M, Roelfsema F 1997 Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing’s disease. Eur J Endocrinol 136:394–400[Abstract/Free Full Text]
  60. Veldman RG, van den Berg G, Pincus SM, Frolich M, Veldhuis JD, Roelfsema F 1999 Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas. Eur J Endocrinol 140:192–200[Abstract]
  61. Veldhuis JD, Liem AY, South S, et al. 1995 Differential impact of age, sex-steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 80:3209–3222[Abstract]
  62. Pincus SM, Gevers E, Robinson ICAF, et al. 1996 Females secrete growth hormone with more process irregularity than males in both human and rat. Am J Physiol 270:E107–E115
  63. Veldhuis JD, Metzger DL, Martha Jr PM, et al. 1997 Estrogen and testosterone, but not a non-aromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab 82:3414–3420[Abstract/Free Full Text]
  64. Pincus SM, Hartman ML, Roelfsema F, Thorner MO, Veldhuis JD 1999 Hormone pulsatility discrimination via coarse and short time sampling. Am J Physiol 277:E948–E957
  65. Veldhuis JD, Straume M, Iranmanesh A, et al. 2001 Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. Am J Physiol 280:R721–R729
  66. Gevers E, Pincus SM, Robinson ICAF, Veldhuis JD 1998 Differential orderliness of the GH release process in castrate male and female rats. Am J Physiol 274:R437–R444
  67. Veldhuis JD, Johnson ML, Faunt LM, Seneta E 1994 Assessing temporal coupling between two, or among three or more, neuroendocrine pulse trains: cross-correlation analysis, simulation methods, and conditional probability testing. Methods Neurosci 20:336–376
  68. Mulligan T, Iranmanesh A, Johnson ML, Straume M, Veldhuis JD 1997 Aging alters feedforward and feedback linkages between LH and testosterone in healthy men. Am J Physiol 42:R1407–R1413
  69. Veldhuis JD, Iranmanesh A, Mulligan T, Pincus SM 1999 Disruption of the young-adult synchrony between luteinizing hormone release and oscillations in follicle-stimulating hormone, prolactin, and nocturnal penile tumescence (NPT) in healthy older men. J Clin Endocrinol Metab 84:3498–3505[Abstract/Free Full Text]
  70. Licinio J, Mantzoros C, Negrao AB, et al. 1997 Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nature 3:575–579
  71. Agarwal SK, Vogel K, Weitsman SR, Magoffin DA 1999 Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J Clin Endocrinol Metab 84:1072–1076[Abstract/Free Full Text]
  72. Brannian JD, Zhao Y, McElroy M 1999 Leptin inhibits gonadotrophin-stimulated granulosa cell progesterone production by antagonizing insulin action. Hum Reprod 14:1445–1448[Abstract/Free Full Text]
  73. Zachow RJ, Magoffin DA 1997 Direct intraovarian effects of leptin: impairment of the synergistic action of insulin-like growth factor-1 on follicle-stimulating hormone-dependent E2–17ß production by rat ovarian granulosa cells. Endocrinology 138:847–850[Abstract/Free Full Text]
  74. Licinio J, Negrao AB, Mantzoros C, et al. 1998 Synchronicity of frequently-sampled 24-hour concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. Proc Natl Acad Sci USA 95:2541–2546[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. Alesci, P. E. Martinez, S. Kelkar, I. Ilias, D. S. Ronsaville, S. J. Listwak, A. R. Ayala, J. Licinio, H. K. Gold, M. A. Kling, et al.
Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2522 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Ghizzoni, G. Mastorakos, A. Vottero, M. Ziveri, I. Ilias, and S. Bernasconi
Spontaneous Growth Hormone (GH) Secretion Is Not Directly Affected by Ghrelin in Either Short Normal Prepubertal Children or Children with GH Neurosecretory Dysfunction
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5488 - 5495.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Silfen, M. R. Denburg, A. M. Manibo, R. A. Lobo, R. Jaffe, M. Ferin, L. S. Levine, and S. E. Oberfield
Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4682 - 4688.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Barontini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Barontini, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*17ALPHA-HYDROXYPROGESTERONE
*ESTRADIOL
*ESTRONE
*MENOTROPINS
*TESTOSTERONE

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals